CN106456764A8 - 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂 - Google Patents

用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂 Download PDF

Info

Publication number
CN106456764A8
CN106456764A8 CN201580028585.0A CN201580028585A CN106456764A8 CN 106456764 A8 CN106456764 A8 CN 106456764A8 CN 201580028585 A CN201580028585 A CN 201580028585A CN 106456764 A8 CN106456764 A8 CN 106456764A8
Authority
CN
China
Prior art keywords
pdl
antagonist
hpv negative
treating hpv
negative cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580028585.0A
Other languages
English (en)
Other versions
CN106456764A (zh
Inventor
K.斯特尔
M.C.雷贝拉托
J.A.巴拉克-哈斯金斯
P.B.罗宾斯
J.R.瓦塞利
R.A.斯图尔特
R.伊布拉希姆
A.沙拉比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of CN106456764A publication Critical patent/CN106456764A/zh
Publication of CN106456764A8 publication Critical patent/CN106456764A8/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

在此提供的是治疗HPV阴性肿瘤的方法，该方法包括给予有效量的PDL-1/PD-1相互作用的拮抗剂(例如，抗PDL-1或抗PD-1抗体或其抗原结合片段)。
CN201580028585.0A 2014-05-29 2015-05-28 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂 Pending CN106456764A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004731P 2014-05-29 2014-05-29
US62/004,731 2014-05-29
PCT/EP2015/061909 WO2015181331A1 (en) 2014-05-29 2015-05-28 Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers

Publications (2)

Publication Number Publication Date
CN106456764A CN106456764A (zh) 2017-02-22
CN106456764A8 true CN106456764A8 (zh) 2017-06-30

Family

ID=53276122

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580028585.0A Pending CN106456764A (zh) 2014-05-29 2015-05-28 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂

Country Status (13)

Country Link
US (1) US20160031990A1 (zh)
EP (1) EP3149043A1 (zh)
JP (1) JP2017517525A (zh)
KR (1) KR20170007750A (zh)
CN (1) CN106456764A (zh)
AU (1) AU2015265859A1 (zh)
BR (1) BR112016027881A2 (zh)
CA (1) CA2949327A1 (zh)
IL (1) IL248836A0 (zh)
RU (1) RU2016151757A (zh)
SG (1) SG11201609468WA (zh)
TW (1) TW201625300A (zh)
WO (1) WO2015181331A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
WO2016030455A1 (en) * 2014-08-28 2016-03-03 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3322732A2 (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
HUE053966T2 (hu) * 2015-07-14 2021-08-30 Bristol Myers Squibb Co Eljárás rák kezelésére immunellenõrzõpont inhibitorral, antitest, amely köt programozott halál-1 receptorhoz (PD-1) vagy programozott halál ligandum 1-hez (PD-L1)
MA48579A (fr) 2015-09-01 2020-03-18 Agenus Inc Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
MX2019002946A (es) 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos.
WO2018222949A1 (en) 2017-06-01 2018-12-06 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
US11813279B2 (en) * 2018-12-21 2023-11-14 Aim Immunotech Inc. Compositions for cancer therapy and methods
CN115551538A (zh) * 2020-01-21 2022-12-30 拓维创新生物科技(香港)有限公司 干扰IL-1β受体信号转导的药剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101573109B1 (ko) * 2009-11-24 2015-12-01 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
MY186099A (en) * 2012-05-31 2021-06-22 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
WO2015034519A1 (en) * 2013-09-03 2015-03-12 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
KR20240056664A (ko) * 2013-09-11 2024-04-30 메디뮨 리미티드 종양 치료용 항-ｂ7-ｈ1 항체

Also Published As

Publication number Publication date
US20160031990A1 (en) 2016-02-04
AU2015265859A1 (en) 2016-12-15
TW201625300A (zh) 2016-07-16
CA2949327A1 (en) 2015-12-03
SG11201609468WA (en) 2016-12-29
BR112016027881A2 (pt) 2017-10-24
RU2016151757A (ru) 2018-07-02
WO2015181331A1 (en) 2015-12-03
EP3149043A1 (en) 2017-04-05
CN106456764A (zh) 2017-02-22
JP2017517525A (ja) 2017-06-29
KR20170007750A (ko) 2017-01-20
IL248836A0 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
CN106456764A8 (zh) 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂
MX2022002364A (es) Anticuerpos anti-pd-l1.
WO2016014688A3 (en) Anti-pd-1 antibodies
EP3689909A4 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
WO2018093821A8 (en) Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12016501456A1 (en) Antibody molecules to pd-1 and uses thereof
MX2020010530A (es) Anticuerpos humanizados contra cd269 (bcma).
EP3604337A4 (en) B7-H3 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF THE SAME, AND ITS MEDICAL USE
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
MX2022014695A (es) Anticuerpos anti-gitr y sus usos.
EP3552665A3 (en) Antibodies
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
PH12016501366A1 (en) Novel anti-baff antibodies
EP3712170A4 (en) CD96 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
PH12019500552A1 (en) Antibody specifically binding to pd-1 and functional fragment thereof
EP3500294A4 (en) ANTI-PD-1 ANTIBODIES OR FRAGMENTS THEREOF FOR TREATING HEPATITIS B
EP3192527A4 (en) Cancer-cell-specific antibody, anticancer agent, and cancer testing method
EA201792058A1 (ru) Виротерапия комбинацией антител
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
EP3730519A4 (en) ANTIBODY OR ANTIGENT BINDING FRAGMENT THEREOF FOR THE SPECIFIC DETECTION OF B-CELL MALIGNOMAS, CHIMERA ANTIGEN RECEPTOR THEREOF AND USE THEREOF
WO2018102594A8 (en) Methods of treating solid tumors with anti-cd200 antibodies
EP3401336A4 (en) PCSK9 ANTIBODIES, ANTI-BINDING FRAGMENT THEREOF AND MEDICAL USES THEREOF

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: 62/004,731 2014.05.29 US

Number: 08

Volume: 33

CI01 Publication of corrected invention patent application
CI02 Correction of invention patent application

Correction item: Priority

Correct: 62/004,731 2014.05.29 US

Number: 08

Page: The title page

Volume: 33

CI02 Correction of invention patent application
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170222

WD01 Invention patent application deemed withdrawn after publication